Results 11 to 20 of about 5,427 (131)
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. [PDF]
PLoS ONE, 2015 We investigated the sensitivity of intrahepatic cholangiocarcinoma (IHCCA) subtypes to chemotherapeutics and molecular targeted agents. Primary cultures of mucin- and mixed-IHCCA were prepared from surgical specimens (N.
Alice Fraveto +15 more
doaj +1 more source
A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. [PDF]
PLoS ONE, 2016 While advances in high-throughput screening have resulted in increased ability to identify synergistic anti-cancer drug combinations, validation of drug synergy in the in vivo setting and prioritization of combinations for clinical development remain low-
Joyoti Dey +10 more
doaj +1 more source
Journal of International Medical Research, 2022 There is heterogeneity in cancer patients’ responses to immune checkpoint inhibitors (ICIs), including hyperprogression, which is very rapid tumor progression following immunotherapy, and pseudoprogression, which is an initial increase followed by a ...
Yong Da +8 more
doaj +1 more source
Frontiers in Oncology, 2022 BackgroundIrreversible electroporation (IRE) has emerged as a viable consolidative therapy after induction chemotherapy, in which this combination has improved overall survival of locally advanced pancreatic cancer (LAPC).
Matthew R. Woeste +6 more
doaj +1 more source
Metastatic melanoma – a review of current and future drugs
Drugs in Context, 2012 Background: Melanoma is one of the most aggressive cancers, and it is estimated that 76,250 men and women will be diagnosed with melanoma of the skin in the USA in 2012.
Tiago Rodrigues Velho
doaj +1 more source
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use [PDF]
Farmacia Hospitalaria, 2015 Objective: To evaluate the results obtained with the combined use of nab-paclitaxel and gemcitabine in the treatment of patients with metastatic pancreatic adenocarcinoma. Materials and methods: Retrospective observational study.
Elena Ferris Villanueva +5 more
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2020 Merkel cell carcinoma (MCC) is a rare aggressive form of skin cancer originating in neuroendocrine cells. The antiprogrammed death ligand 1 (PD-L1) monoclonal antibody (mAb) avelumab has been approved for treatment of MCC, but options are limited, should
Andrew Nguyen +6 more
doaj +1 more source
Frontiers in Pharmacology, 2018 Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients.Methods: Three randomized, open-label, two-period crossover ...
Qingmei Li +8 more
doaj +1 more source
Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response
iScience, 2021 Summary: Taxane-based reagents, such as Taxol, Taxotere, and Abraxane, are popular anti-cancer drugs that can differ in their clinical efficacy. This difference is generally attributed to their active pharmaceutical ingredients.
Qian Dai +13 more
doaj +1 more source
Artificial Cells, Nanomedicine, and Biotechnology, 2019 Plastin 3 (PLS3) overexpression may serve as a marker for predicting chemotherapeutic outcomes in drug-resistant cancer cells, but the mechanism is unclear.
Yan Ma +6 more
doaj +1 more source